目的 调查分析新型冠状病毒肺炎(COVID-19)诊疗国际信息资源的现状,为疫情防控提供参考。方法 系统检索并总结世界卫生组织(WHO)、美国疾病控制与预防中心(CDC)、欧洲疾病预防控制中心(ECDC)、澳大利亚卫生部(AGDH)、英国卫生部(UKDH)和国际药学联合会(FIP)发布的COVID相关信息,描述性评价信息时效性、完备性与适用性,并分析临床诊疗与药师药学工作的相关指南。结果 WHO、CDC、ECDC、AGDH、UKDH和FIP相关信息内容详实,均具备时效性、完备性与一定的适用性,其中WHO侧重于全球视野并提供了临床诊疗指南,FIP提供了侧重于药师药学工作并提供了治疗药物相关信息。结论 参考相关国际信息资源时,应结合实际情况进行审慎解读与应用,以促进COVID-19疫情预防与控制。
Abstract
OBJECTIVE To analyze and evaluate the international information about coronavirus disease 2019 (COVID-19), and provide reference for prevention and control of the epidemic. METHODS International information about COVID-19 from World Health Organization (WHO), Centers for Disease Control and Prevention, US (CDC), European Centre for Disease Prevention and Control (ECDC), Department of Health, Australian Government (AGDH), Department of Health & Social Care, UK (UKDH), the International Pharmaceutical Federation (FIP) were retrieved and summarized. The timeliness, comprehensiveness and applicability of the international information were evaluated descriptively. Technical guidance about clinical management and pharmaceutical work of pharmacists were analyzed. RESULTS Information from WHO, CDC, ECDC, AGDH, UKDH and FIP were generally detailed, with timeliness, comprehensiveness and a certain applicability. WHO focused on global perspective and provided clinical management guidance, and FIP focused on pharmacist and pharmaceutical work and provided information about clinical medication. CONCLUSION When referring to international information about COVID-19, the actual situation should be taken into consideration, and subsequently the information should be applied cautiously to help prevent and control the epidemic of COVID-19.
关键词
新型冠状病毒 /
COVID-19 /
诊疗 /
信息资源 /
分析评价
{{custom_keyword}} /
Key words
SARS-CoV-2 /
COVID-19 /
clinical management /
international information /
analysis /
evaluation
{{custom_keyword}} /
中图分类号：
R95
R563
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHAO R S, YANG Y H, YANG L, et al. Coronavirus SARS-CoV-2 infection: expert consensus on guidance and prevention strategies for hospital pharmacists and the pharmacy workforce (2nd edition) [J]. Chin Pharm J (中国药学杂志), 2020, 55(4):268-277.
[2] WORLD HEALTH ORGANIZATION (WHO). "Coronavirus disease (COVID-19) outbreak" [EB/OL]. WHO , 2020. [2020-05-15]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[3] CENTERS FOR DISEASE CONTROL AND PREVENTION, US (CDC). "Coronavirus Disease 2019 (COVID-19)" [EB/OL]. CDC, 2020. [2020-04-19]. https://www.cdc.gov/coronavirus/2019-ncov/summary.html.
[4] EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (ECDC). "COVID-19" [EB/OL]. ECDC, 2020. [2020-02-28]. https://www.ecdc.europa.eu/en/novel-coronavirus-china.
[5] DEPARTMENT OF HEALTH, AUSTRALIAN GOVERNMENT (AGDH). " Coronavirus (COVID-19) health alert" [EB/OL]. AGDH,2020. [2020-05-18]. https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert.
[6] DEPARTMENT OF HEALTH & SOCIAL CARE, U.K. (UKDH). "Coronavirus (COVID-19): latest information and advice" [EB/OL]. UKDH, 2020. [2020-05-18]. https://www.gov.uk/guidance/wuhan-novel-coronavirus-information-for-the-public.
[7] THE INTERNATIONAL PHARMACEUTICAL FEDERATION (FIP). "SARS-CoV-2 outbreak preparedness" [EB/OL]. FIP, 2020. [2020-05-18]. https://www.fip.org/coronavirus.
[8] HULKOWER R L, CASANOVA L M, RUTALA W A, et al. Inactivation of surrogate coronaviruses on hard surfaces by health care germicides[J]. Am J Infect Contr, 2011, 39(5):401-407.
[9] SATTAR S A, SPRINGTHORPE V S, KARIM Y, et al. Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses[J]. Epidemiol Infect, 1989, 102(3):493-505.
[10] LAI M Y Y, CHENG P K C, LIM W W L. Survival of severe acute respiratory syndrome coronavirus[J]. Clin Infect Dis, 2005, 41(7):e67-e71.
[11] SAKNIMIT M, INATSUKI I, SUGIYAMA Y, et al. Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals[J]. Jikken Dobutsu, 1988, 37(3):341-345.
[12] NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Clinical management of human infection with novel coronavirus(COVID-19) (Interim guidance v7)[EB/OL].[2020-03-04]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[13] THE INTERNATIONAL PHARMACEUTICAL FEDERATION (FIP). SARS-CoV-2 outbreak: Information and interim guidelines for pharmacists and the pharmacy workforce [J]. Chin Pharm J(中国药学杂志), 2020, 55(4):249-267.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技重大专项“重大新药创制专项课题”项目资助(2017ZX09304012-008)
{{custom_fund}}
PDF(3772 KB)
